Janux Therapeutics, Inc.
NASDAQ:JANX
54.21 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 8.083 | 8.612 | 3.637 | 0 | 0 |
| Cost of Revenue
| 1.955 | 0.841 | 0.113 | 0.013 | 0.006 |
| Gross Profit
| 6.128 | 7.771 | 3.524 | -0.013 | -0.006 |
| Gross Profit Ratio
| 0.758 | 0.902 | 0.969 | 0 | 0 |
| Reseach & Development Expenses
| 54.922 | 53.441 | 26.237 | 3.041 | 2.999 |
| General & Administrative Expenses
| 26.14 | 22.262 | 10.329 | 1.802 | 0.772 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 |
| SG&A
| 26.14 | 22.262 | 10.329 | 1.802 | 0.772 |
| Other Expenses
| -54.922 | 4.032 | 0.257 | -1.735 | 0 |
| Operating Expenses
| 81.062 | 75.703 | 36.566 | 4.843 | 3.771 |
| Operating Income
| -72.979 | -67.091 | -32.929 | -4.843 | -3.771 |
| Operating Income Ratio
| -9.029 | -7.79 | -9.054 | 0 | 0 |
| Total Other Income Expenses Net
| 14.686 | 4.032 | 0.257 | -1.941 | -0.233 |
| Income Before Tax
| -58.293 | -63.059 | -32.672 | -6.784 | -4.004 |
| Income Before Tax Ratio
| -7.212 | -7.322 | -8.983 | 0 | 0 |
| Income Tax Expense
| 1.787 | -8.905 | -0.113 | -1.529 | 0.233 |
| Net Income
| -58.293 | -54.154 | -32.559 | -5.255 | -4.237 |
| Net Income Ratio
| -7.212 | -6.288 | -8.952 | 0 | 0 |
| EPS
| -1.32 | -1.31 | -0.79 | -0.13 | -0.1 |
| EPS Diluted
| -1.32 | -1.31 | -0.79 | -0.13 | -0.1 |
| EBITDA
| -71.024 | -67.091 | -32.929 | -6.565 | -3.765 |
| EBITDA Ratio
| -8.787 | -7.79 | -9.054 | 0 | 0 |